Johnson & Johnson today announced promising new results from the Phase 1b/2 OrigAMI-4 study evaluating the efficacy and safety of subcutaneous (SC) amivantamab monotherapy in patients with human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback